VOLUME 1 (2010)
Table of Contents
Editorial
|
| Shapeshifting and tumor suppression by PLZF |
|
https://doi.org/10.18632/oncotarget.102
|
| 3-5 |
Reviews
|
| Bortezomib: killing two birds with one stone in gastrointestinal stromal tumors |
|
https://doi.org/10.18632/oncotarget.103
|
| 6-8 |
Research Papers
|
| Smooth muscle αactin is a direct target of PLZF: effects on the cytoskeleton and on susceptibility to oncogenic transformation |
|
https://doi.org/10.18632/oncotarget.104
|
| 9-21 |
|
| Overexpression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drugresistance |
|
https://doi.org/10.18632/oncotarget.105
|
| 22-33 |
|
| Phase 2 clinical trial of 5azacitidine valproic acid and alltrans retinoic acid in patients with highrisk acute myeloid leukemia or myelodysplastic syndrome |
|
https://doi.org/10.18632/oncotarget.106
|
| 34-42 |
Research Perspectives
|
| The tumor suppressor p53 connects ribosome biogenesis to cell cycle control: a doubleedged sword |
|
https://doi.org/10.18632/oncotarget.107
|
| 43-47 |
|
| ID4: a new player in the cancer arena |
|
https://doi.org/10.18632/oncotarget.108
|
| 48-58 |
|
| A critical role for the NFkB pathway in multiple myeloma |
|
https://doi.org/10.18632/oncotarget.109
|
| 59-68 |
|
| Targeting TOR dependence in cancer |
|
https://doi.org/10.18632/oncotarget.110
|
| 69-76 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLCß